AeroVanc

AeroVanc is an experimental medication designed to treat lung infections caused by the bacteria *Pseudomonas aeruginosa*, which commonly affect people with cystic fibrosis. It combines an antibiotic called vancomycin with a special delivery system that delivers the drug directly into the lungs via inhalation. This targeted approach aims to effectively fight the bacteria while reducing side effects compared to traditional intravenous treatment. AeroVanc is still in clinical trials, but it represents an innovative effort to improve infection management and quality of life for cystic fibrosis patients.